Research map: Antibody peptide conjugates as multifunctional therapeutics: Mechanisms, challenges, and prospects
Back to the article
Papers in this map
- Autophagy in the Pathogenesis of Disease · Beth Levine · 2008 · 7143 citations · Cited by this paper
- Inflammation in atherosclerosis: drivers, mechanisms and therapies · 2026 · Related
- Matrix Metalloproteinases: Regulators of the Tumor Microenvironment · Kai Kessenbrock · 2010 · 5159 citations · Cited by this paper
- Stimulate-and-retain hydrogel strategy integrating oncolytic virus and oxaliplatin for dual ICD-inducing antitumor immunity · 2026 · Related
- Trends in peptide drug discovery · Markus Muttenthaler · 2021 · 2025 citations · Cited by this paper
- Modulating macrophage efferocytosis: Drug delivery strategies for enhancement, mimicry, and inhibition · 2026 · Related
- Autophagy pathway: Cellular and molecular mechanisms · Li Yu · 2017 · 1537 citations · Cited by this paper
- Editor Profiles: Guest Editors of the Special Column on Machine Learning in Drug Discovery · 2026 · Related
- The coming of age of chaperone-mediated autophagy · Susmita Kaushik · 2018 · 1419 citations · Cited by this paper
- Targeting senescent cells with dipeptidyl peptidase 4–CAR–NK cells alleviates liver fibrosis and reverses metabolic dysfunction · 2026 · Related
- Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate · Kevin J. Hamblett · 2004 · 1253 citations · Cited by this paper
- SARS-CoV-2 inhibits EBV-dependent tumor proliferation through PLpro-mediated degradation of EBNA1 · 2026 · Related
- Development of potent monoclonal antibody auristatin conjugates for cancer therapy · Svetlana O. Doronina · 2003 · 1216 citations · Cited by this paper
- Nano-drug delivery systems of natural products in cardiovascular therapy: From mechanistic insights to precision targeting · 2026 · Related
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 · Yusuke Ogitani · 2016 · 1193 citations · Cited by this paper
- Reaction-aware molecular representation learning: Toward generalizable artificial intelligence for enzymatic catalysis · 2026 · Related
- Unlocking the potential of antibody–drug conjugates for cancer therapy · Joshua Z. Drago · 2021 · 1164 citations · Cited by this paper
- Neuroprotection by YZG-331 in postoperative cognitive dysfunction via Mg2+-dependent blockade of NMDA receptors · 2026 · Related
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors · Kazuki N. Sugahara · 2009 · 1151 citations · Cited by this paper
- Unveiling the mechanisms of comorbidity of aging and depression: A perspective based on early life stress (ELS) · 2026 · Related
- The Current State of Peptide Drug Discovery: Back to the Future? · Antoine Henninot · 2017 · 1138 citations · Cited by this paper
- Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs · Kazuki N. Sugahara · 2010 · 1091 citations · Cited by this paper
- The Role of Mechanical Forces in Tumor Growth and Therapy · Rakesh K. Jain · 2014 · 1064 citations · Cited by this paper
- Describing the Mechanism of Antimicrobial Peptide Action with the Interfacial Activity Model · William C. Wimley · 2010 · 1026 citations · Cited by this paper
- Identification of essential genes for cancer immunotherapy · Shashank J. Patel · 2017 · 915 citations · Cited by this paper
- Enhanced antibody half-life improves in vivo activity · Jonathan Zalevsky · 2010 · 670 citations · Cited by this paper
- Advances in oral peptide therapeutics · Daniel J. Drucker · 2019 · 656 citations · Cited by this paper
- Exploring the next generation of antibody–drug conjugates · Kyoji Tsuchikama · 2024 · 632 citations · Cited by this paper
- LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation · Green Ahn · 2021 · 626 citations · Cited by this paper
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial · Henry Miles Prince · 2017 · 593 citations · Cited by this paper
- Mechanism of Antimicrobial Peptides: Antimicrobial, Anti-Inflammatory and Antibiofilm Activities · Ying Luo · 2021 · 559 citations · Cited by this paper
- Antibody-drug conjugates—an emerging class of cancer treatment · Nikolaos G. Diamantis · 2016 · 532 citations · Cited by this paper
- Antimicrobial peptides as therapeutic agents: opportunities and challenges · Margit Mahlapuu · 2020 · 490 citations · Cited by this paper
- Identification and Design of Peptides as a New Drug Delivery System for the Brain · Michel Demeule · 2007 · 467 citations · Cited by this paper
- Antimicrobial peptides in animals and their role in host defences · Kim A. Brogden · 2003 · 460 citations · Cited by this paper
- Humanized mouse models for immuno-oncology research · Jane Chuprin · 2023 · 412 citations · Cited by this paper
- Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs) · Bethany M. Cooper · 2020 · 407 citations · Cited by this paper
- Antibody–drug conjugates: Recent advances in linker chemistry · Zheng Su · 2021 · 404 citations · Cited by this paper
- Discovery of antimicrobial peptides in the global microbiome with machine learning · Célio Dias Santos Júnior · 2024 · 403 citations · Cited by this paper
Source: OpenAlex (CC0)